<DOC>
	<DOC>NCT00336479</DOC>
	<brief_summary>Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels</brief_summary>
	<brief_title>Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Hepatitis C virus Genotype 1 with detectable plasma hepatitis C virus RNA Have been infected with hepatitis C virus for greater than (&gt;) 6 months Seronegative for hepatitis B surface antigen and Human Immunodeficiency Virus 1 and 2 Must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented nonchildbearing potential) Female subjects must have a negative pregnancy test at all visits before the first dose Received any approved or investigational drug or drug regimen for the treatment of hepatitis C Any medical contraindications to Pegylated Interferon Alfa 2a or Ribavirin therapy Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to, hepatitis B, drug or alcoholrelated cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, Nonalcoholic Steatohepatitis or primary biliary cirrhosis Diagnosed or suspected hepatocellular carcinoma Histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before study start Alcohol abuse or excessive use in the last 12 months Participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>